Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > Drug Discovery Re-Invented

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Drug Discovery Re-Invented

Emerging Role of Biotechs, Academics and Non-Profits

16 Oct 2013 - 19 Oct 2013

Scottsdale, Arizona, USA


The Drug Discovery Re-Invented Fusion conference will center on new approaches to drug discovery in an industry where the landscape is changing rapidly. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models. The conference will also provide examples of successful strategies for advancing new drug candidates in this era of distributed discovery.

Key Sessions include:

  1. Discovery Re-Invented
  2. Novel Pharma Approaches
  3. Collaborative Drug Discovery
  4. Natural Products
  5. Structure, Modelling and Informatics
  6. Biologics and Non-traditional Therapeutics
  7. Discovery Technologies
  8. Exhibit

Dr. William A. Kinney's Bio:

Dr. Kinney began his industrial career in the CNS group at Wyeth, where he invented the cyclobutenedione-containing NMDA antagonist perzinfotel that progressed to phase II clinical trials for pain.  At Magainin Pharmaceuticals, he directed projects on trodusquemine (phase II, obesity) and squalamine (phase II, eye disease), two shark-derived natural products.  In 2000, he joined Johnson & Johnson, where he pursued peptide-mimetic integrin antagonists and urotensin-II receptor modulators for cardiovascular indications.  He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation.  Currently, Dr. Kinney is a faculty member within the Institute for Hepatitis and Virus Research.  He directed the technical feasibility, business plan development, and logistics for the donation of the former Merck Research Laboratories Natural Product Collection to the IHVR. He also initiated a structure based drug design project on a new anti-viral target in collaboration with Prof. Peter Katsikis at Drexel University to develop PI3K p110d kinase inhibitors that block host cell signaling pathways required for influenza infection and pathogenesis.  He is an adjunct faculty member atDrexelUniversityand Founder of IteraMed, a company focused on internal and out-sourced organic synthesis, consulting, and drug discovery.  His scientific contributions include 70 publications, invited lectures, and oral presentations and inventorship on 37 issued U.S. patents. 

Dr. Charles H. Reynolds' Bio:

Dr. Reynolds is currently President of GFree, LLC, a structure-based drug discovery company based in suburban Philadelphia.  He is an expert in the areas of computational chemistry, structure-based design, and drug discovery with more than 25 years of experience.  Dr. Reynolds is also a Director on the Advisory Board of Quantum Bio, Inc. and an adjunct professor at the Pennsylvania Drug Discovery Institute.  Previously he was Senior Director and Head of Discovery Technologies at Ansaris, where he was a member of the executive leadership team and responsible for the company’s proprietary fragment-based design technology platform.  Prior to joining Ansaris, he led modeling groups at the Springhouse, PA and La Jolla, CA research sites of Johnson & Johnson, where he and his team made significant contributions to discovery programs in neuroscience, oncology, pain, and cardiovascular disease.  Dr. Reynolds began his career at Rohm and Haas (now Dow) where his scientific accomplishments were recognized with the company’s highest science award, the Otto Haas Award.  He has held a variety of leadership positions in the American Chemical Society (ACS), and was recently named a Fellow of the ACS.  Some of his other awards include The Standards of Leadership Award (J&J) and Excellence in Science Award (J&J).
Dr. Reynolds earned a BA, with honors, from Austin College and PhD from the University of Texas at Austin.  He was an adjunct professor at the University of Pennsylvania and has supervised joint graduate and postdoctoral students at the Pennsylvania State University and the University of North Carolina at Chapel Hill. He has published approximately 100 papers, patents, and book chapters, and is a co-editor of two books.  His comments on drug discovery have been sought by news organizations ranging from C&E News to the Wall Street Journal.




Wednesday, October 16, 2013

15:30 – 17:00

Registration & Reception


17:00 – 17:15

Opening  Comments


Discovery Re-Invented
Session Chair: C. Reynolds

17:15 – 18:00

Steve Young
Retired VP Merck & Co.

HIV Integrase Inhibitors: The Chemistry Behind The Discovery of Isentress

18:00 – 18:30

James Breitenbucher
Dart Neuroscience

Drug Discovery – What really needs to be “Re-Invented”?

18:30 – 19:00

Bart DeCorte
Janssen Pharmaceutical Companies of Johnson & Johnson

The Janssen Incubator – A Novel Business Model to Spark Internal Innovation

19:00 - 20:00

Welcome Reception/Dinner

Novel Pharma Approaches
Session Chair: P. Lam

20:00 – 20:30

Patrick Lam
Lam Drug Discovery Consulting, LLC

Discovery of Eliquis®/Apixaban, a novel FXa anticoagulant

20:30 – 21:00

Serge Boulet
Eli Lilly and Company

Phenotypic Drug Discovery of Novel Anti-Angiogenics

21:00 – 21:30

Gabor Butora

Chemically Modified Oligonucleotides for RNAi

21:30 -22:00

Michael Trzoss
Trius Therapeutics

Novel GyrB/ParE Inhibitors


Free Time

Thursday, October 17, 2013

06:00 – 08:00


Collaborative Drug Discovery I
Session Chairs: J. Vacca and B. Kinney

08:00 – 08:45

Michael Foley
Broad Institute


08:45 – 09:15

Craig Thomas
National Center for Advancing Clinical and Therapeutic Sciences

Associative Data Profiles Connect Basic Research to Translational Efforts

09:15 – 09:45

Todd Chappell
BioHealth Innovation, Inc.

Entrepreneurs-in-Residence, Not Just for Venture Capitalists

09:45 – 10:15

James Barrow
Lieber Institute

Genetics-Driven Psychiatry Drug Discovery

10:15 – 10:30

Greg Miknis
Colorado Center for Drug Discovery

Promoting Colorado Drug Discovery Research: Creation of the Colorado Center for Drug Discovery (C2D2)

10:30 – 11:00


11:00 – 11:30

Joseph Vacca
WuXi Apptec

"Drug Discovery in the 21st Century"

11:30 – 12:00

Zhengying Pan
Peking University, Shenzhen Graduate School

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

12:00 – 12:15

Barry Bunin
Collaborative Drug Discovery

Collaborative Drug Discovery Technology Neglected, Infectious, CNS, and Repositioning Applications

12:15 – 12:30

Olanrewaju Omobuwajo
Niger Delta University

Fertility reducing effect of pandanus candelabrum p.beauv. Leaves in male wistar rats

12:30 – 13:15

Group Lunch

12:30 – 16:30

Free Time

Natural Products
Session Chair: M. Goetz

16:30 – 16:45

Michael Goetz

The Natural Products Discovery Institute. Classical and novel approaches to drug discovery

16:45 – 17:30

Sean Brady
Rockefeller University

Watch where you step, there is new chemistry everywhere

17:30 – 18:00

Jef De Brabander
UT Southwestern Medical Center

Opportunities for Lead Discovery in a Biomedical Research Environment

18:00 – 18:20

Guy Carter

Biosortia Pharmaceuticals

A deep dive into aquatic microbial consortia for drug discovery

18:20 – 18:40

Jetze Tepe
Michigan State University


Non-competitive regulation of the human proteasome by natural products and natural product inspired scaffolds

18:40 – 19:00

Phillip Cox


Development of poppy varieties to suit changing market requirements

19:00 – 20:00

Group Dinner

20:00 – 22:00

Poster Session & Cocktail Reception

Friday, October 18, 2013

06:00 – 08:00

Breakfast & Free Morning

12:00 – 12:45

Group Lunch

Structure, Modeling and Informatics
Session Chair: C. Reynolds

12:45 13:30

William Jorgensen
Yale University

Drug Discovery Accelerated by Computational Methods

13:30 – 14:00

Kenneth Merz
University of Florida

Blurring to Bring Binding Free Energies into Focus

14:00 – 14:30

Chris Williams
Chemical Computing Group

Water Placement - Application of 3D-RISM to structure-based drug design

14:30 – 14:45

Christopher Reynolds
University of Essex

Unravelling similarities between class A and class B GPCRs through modelling and mutagenesis

14:45 – 15:00

Lance Westerhoff
QuantumBio Inc.

Quantum mechanics-based macromolecular x-ray refinement as an advanced method for the high throughput crystallography

15:00 – 15:30

Leah Frye

Nimbus and Schrödinger Reinventing Drug Discovery: Rapid and Efficient Development of Acetyl-CoA Carboxylase Inhibitors

15:30 – 16:00

Paul Leeson

Compound Quality: What Have We Learned?

16:00 - 16:30


Biologics and Non-traditional Therapeutics
Session Chair: C. Reynolds

16:30 – 17:15

David Lowe

Targeting the Amino Acid Dependence of Cancer

17:15 – 17:45

Andreas Bader
Mirna Therapeutics

MRX34 – from bench to bedside

17:45 – 18:15

David Gorenstein
University of Texas HSC Houston

Next Generation X-Aptamers for Personalized Nanomedicine

18:15 – 18:45

Aaron Sato
Sutro Biopharma

Rapid Design and Production of Homogeneous Best-in-Class Protein Therapeutics using Cell-Free Protein Expression

18:45 – 19:00

Ian Pottie

Mount Saint Vincent University  

Developing an Imaging Agent for Cholinesterase Enzymes to

Diagnose Alzheimer’s Disease

19:00 – 19:30


Foundation Support for Neglected Diseases
Session Chair: L. Trundle

19:30 – 20:15

Omar Vandal
Bill & Melinda Gates Foundation

Partnerships in Drug Discovery and Technology Development for Diseases of the Developing World

20:30 – 00:00

*Gala Night, Group Photo & Poster Awards*

Saturday, October 19, 2013

07:00 – 09:00



Chair Opening

Discovery Technologies
Session Chair: B. Kinney

09:00 – 09:20

Dietmar Wolf


Novel Macrocyclic Libraries Evolved from Natural Product Technology Platforms

09:20 – 09:40

Prem Premsrirut
Mirimus, Inc.

RNAi mouse models: Revolutionizing drug discovery in vivo

09:40 – 10:00

Philip Jones
MD Anderson Cancer Center

Institute for Applied Cancer Science, developing the next generation of oncology agents for targeted patient populations

10:00 – 10:30

Matthew Segall
Optibrium Ltd.

Finding and Applying Rules for Successful Drug Discovery

10:30 – 11:00


11:00 – 11:30

Janet Ralbovsky
University of Tennessee Research Foundation

Technology Transfer Re-invented: How is Academia Adapting to the Changes in Drug Discovery?

11:30 – 12:00

Joel Dudley

Mount Sinai School of Medicine

Developing a Systematic Computational Approach to Identify Novel Drug Indication Relationships Using Public Gene Expression Profiles

12:00 – 12:45

Group Lunch

Collaborative Drug Discovery II
Session Chair: B. DeCorte

12:45 – 13:15

Benjamin Blass
Moulder Center for Drug Discovery Research

Drug Discovery in the Academic Community

13:15 – 13:45

Mark McDonnell
Fox Chase Chemical Diversity Center Inc.

Riluzole prodrugs for melanoma and ALS

13:45 – 14:15

Sandhya Kortagere
Drexel University College of Medicine

Designing protein-protein interaction inhibitors as novel antimalarial chemotherapeutics

14:15 – 14:30

Peter Cheuka
University of Cape Town

Synthesis of aminomethylthiazole analogues for evaluation as antiplasmodial agents

14:30 – 15:00

Kris Josephson

Discovery of Potent Macrocyclic Peptides for Drug Development

15:00 – 15:15

Closing Remarks (Chairs & Fusion)





Plenary Speakers

  • Dr. Steven Young
    Consultant, Retired VP Merck & Co.
  • Dr. Michael Foley
    Director, Chemical Biology, Novel Therapeutics, Broad Institute
  • Prof. William Jorgensen
    Sterling Professor, Yale University
  • Dr Omar Vandal
    Program Officer, Discovery & Translational Sciences, Bill & Melinda Gates Foundation
  • Prof Sean Brady
    Prof, Rockefeller University
  • Dr David Lowe
    CEO, Aeglea BioTherapeutics

Invited Speakers

  • Dr. James Barrow
    Investigator, Lieber Institute
  • Professor Jef De Brabander
    Professor, UT Southwestern Medical Center
  • Dr. Benjamin Blass
    Assistant Professor, Temple University School of Pharmacy, Moulder Center for Drug Discovery Research
  • Dr. Michael Trzoss
    Principal Scientist II, Trius Therapeutics
  • Dr. Joseph Vacca
    Owner, J. Vacca Consulting LLC
  • Prof. Craig Thomas
    Chemistry Technologies Group Leader, NCATS
  • Dr. David Gorenstein
    Assoc. Dean Research, Medical School, University of Texas HSC Houston
  • Dr Michael Goetz
    Director, NPDI, NPDI-IHVR
  • Dr. Leah Frye
    Vice President, Schrodinger
  • Dr. Zhengying Pan
    Research Fellow, Peking University, Shenzhen Graduate School
  • Dr. James Breitenbucher
    Director of Chemistry, Dart Neuroscience
  • Dr. Bart DeCorte
    VP Business Development, Mercachem
  • Professor Kenneth Merz
    Director, Institute for Cyber Enabled Research (iCER) and Joseph Zichis Chair in Chemistry , Michigan State University
  • Dr. Aaron Sato
    VP Research, Sutro Biopharma
  • Mr. Todd Chappell
    Entrepreneur-in-Residence, BioHealth Innovation, Inc.
  • Dr. Sandhya Kortagere
    Assistant Professor, Drexel University College of Medicine
  • Dr. Andreas Bader
    Director - Research, Mirna Therapeutics
  • Dr. Patrick Lam
    Drexel University College of Medicine, Former BMS Chemistry Director
  • Dr. Janet Ralbovsky
    Licensing Associate , University of Tennessee Research Foundation
  • Dr. Serge Boulet
    Senior Research Scientist, Eli Lilly and Company
  • Dr. Mark McDonnell
    Senior Scientist, Fox Chase Chemical Diversity Center Inc.
  • Dr. Paul Leeson
    Consultant, GlaxoSmithKline
  • Dr. Matthew Segall
    CEO, Optibrium Ltd.
  • Dr. Guy Carter
    Chief Scientific Officer, Biosortia Pharmaceuticals
  • Dr. Chris Williams
    Principal Scientist , Chemical Computing Group
  • Dr. Gabor Butora
    Principal Scientist, Merck & Co.
  • Dr. Barry Bunin
    CEO, Collaborative Drug Discovery
  • Dr. Phillip Cox
    Chief Scientist, Noramco Inc
  • Dr. Kristopher Josephson
    Director, Ra Pharmaceuticals


Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr